Two Pediatric Osteosarcoma Cases with Delayed Methotrexate Excretion: Its Clinical Course and Management

High-dose methotrexate (MTX) chemotherapy extends the duration of hospitalization and introduces the risks of serious complications related to delayed MTX excretion. The treatment of delayed MTX excretion is largely dependent on invasive measures such as hemodialysis because the clinical data regard...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Kang Min, Lee, Hee Woo, Kim, Seung Yeon, Lee, Hyeon Jeong, Kim, Dong Hwan, Cho, Joongbum, Kim, Dong Ho, Lim, Jung Sub, Lee, Jin Kyung, Lee, Jun Ah
Formato: Texto
Lenguaje:English
Publicado: Korean Cancer Association 2011
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3072537/
https://www.ncbi.nlm.nih.gov/pubmed/21509165
http://dx.doi.org/10.4143/crt.2011.43.1.67
Descripción
Sumario:High-dose methotrexate (MTX) chemotherapy extends the duration of hospitalization and introduces the risks of serious complications related to delayed MTX excretion. The treatment of delayed MTX excretion is largely dependent on invasive measures such as hemodialysis because the clinical data regarding the efficacy or safety of carboxypetidase G(2) is limited. We report here on the cases of two pediatric osteosarcoma patients with delayed MTX excretion and who were successfully managed using supportive measures. Potential life-threatening complications were prevented by administering high doses of leucovorin.

Ejemplares similares